Modiin Pu (MDIN) AI Stock Analysis

• Market Cap: 34.06M
• Dividend Yield: N/A
• Average Volume (3M): 28.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.14
• Revenue Growth: -17.64%
• EPS Growth: -230.96%
• Country: IL
• Employees: 8
• Sector: Energy
• Sector Strength: 52
• Industry: Oil & Gas Exploration & Production
• EPS (TTM): -0.32
• Shares Outstanding: 34,297,638
• 10 Day Avg. Volume: 18,904
• 30 Day Avg. Volume: 28,000
• PEG Ratio: <0.01
• Price to Book (P/B): 0.30
• Price to Sales (P/S): 0.51
• P/FCF Ratio: -4.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: 90.00 ▼(-3.74% Downside)

Modiin Pu's overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The negative valuation metrics further contribute to a low score, indicating significant risks and challenges.

Modiin Pu Business Overview & Revenue Model

Company Description

Modiin Energy-Limited Partnership engages in the exploration, development, and production of oil and gas assets in the United States and Israel. It holds interests in the Mountainview, GrapeVine, Cassini, and Shideler projects in California; NPB project in Colorado; and Shimshon in Israel. The company was incorporated in 1992 and is based in Tel Aviv-Yafo, Israel.

How the Company Makes Money

Modiin Pu generates revenue through multiple streams, primarily by commercializing its proprietary drug candidates and technologies. The company engages in partnerships with pharmaceutical firms for the co-development of therapeutics, which often includes licensing agreements that provide upfront payments and milestone payments tied to the achievement of specific development goals. Additionally, MDIN earns revenue from selling its drug delivery platforms to other biotech companies. The firm may also receive royalties from successful products that utilize its technologies, thereby creating a diverse revenue model that leverages both direct sales and collaborative ventures within the pharmaceutical industry.

Modiin Pu Financial Statement Overview

Summary

The company faces significant financial challenges with declining revenues and profitability. High leverage and negative net profit margins indicate financial risk, although operational efficiencies are present.

Income Statement

The income statement shows a declining revenue trend with a negative revenue growth rate of -6.49% in the TTM period. The company has struggled with profitability, evidenced by a negative net profit margin of -39.71% and a negative EBIT margin. However, the gross profit margin remains relatively strong at 54.10%, indicating some operational efficiency.

Balance Sheet

The balance sheet reflects high leverage with a debt-to-equity ratio of 2.03 in the TTM period, indicating potential financial risk. The return on equity is negative, suggesting that the company is not generating sufficient returns on shareholders' equity. The equity ratio is not explicitly calculated, but the high debt levels imply a lower equity proportion.

Cash Flow

Cash flow analysis shows a positive operating cash flow, but free cash flow remains negative, indicating cash outflows after capital expenditures. The free cash flow growth rate is positive, suggesting some improvement. However, the free cash flow to net income ratio is negative, highlighting ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.47M	23.09M	27.03M	19.86M	17.64M	1.73M
Gross Profit	12.15M	11.94M	16.03M	13.86M	12.41M	628.00K
EBITDA	9.26M	9.10M	11.99M	9.54M	8.26M	-1.43M
Net Income	-8.92M	-9.45M	2.12M	-2.79M	6.56M	-6.02M
Balance Sheet
Total Assets	118.60M	107.23M	106.09M	80.44M	43.16M	13.68M
Cash, Cash Equivalents and Short-Term Investments	13.31M	2.16M	3.61M	1.63M	1.96M	1.33M
Total Debt	75.24M	58.73M	51.90M	31.18M	16.00M	0.00
Total Liabilities	81.56M	67.79M	66.15M	46.64M	20.25M	1.19M
Stockholders Equity	37.04M	39.44M	39.93M	33.79M	22.91M	12.48M
Cash Flow
Free Cash Flow	-5.11M	-2.88M	-18.94M	-23.81M	-15.52M	-1.29M
Operating Cash Flow	10.09M	10.34M	11.91M	11.69M	8.25M	-233.00K
Investing Cash Flow	-16.55M	-13.60M	-32.07M	-38.96M	-25.62M	-3.11M
Financing Cash Flow	15.92M	1.64M	21.99M	27.13M	18.12M	3.02M

Modiin Pu Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 93.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:MDIN, the sentiment is Negative. The current price of 93.5 is below the 20-day moving average (MA) of 99.01, below the 50-day MA of 111.67, and below the 200-day MA of 146.76, indicating a bearish trend. The MACD of -4.87 indicates Negative momentum. The RSI at 15.37 is Positive, neither overbought nor oversold. The STOCH value of 11.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:MDIN.

Modiin Pu Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	$15.17B	7.61	4.09%	5.20%	3.87%	-62.32%
MDIN	41 Neutral	34.06M	-0.96	―	―	-17.64%	-230.96%